With SPA Finalized, Orexigen To Begin CV Outcomes Study For Contrave In Second Quarter
This article was originally published in The Pink Sheet Daily
Executive Summary
The company expects to be able to re-file the NDA for its obesity candidate by 2014, after 87 major adverse events were recorded in the 10,000-patient, placebo-controlled safety trial.